Clinical Trials Browser

Approved for marketing × futibatinib × 90 days × Clear all

NCT04507503 2026-03-10

Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Approved for marketing

Gastrointestinal

Cholangiocarcinoma